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Many of the reasonable conclusions and recommenda-
tions in Gerald Watts’ review of how to treat patients with
low levels of high-density lipoprotein (HDL)-cholesterol [1]
are based on two conventional and related assumptions.
First, an intervention-induced change of a surrogate
marker (such as HDL-cholesterol) in the desired direction
translates into health benefits (such as reduction in coro-
nary events). Second, it is unimportant which interventions
are used to alter surrogate markers, since an intervention
benefit is independent of the means by which it is
achieved. It seems appropriate to revisit the scientific
bases for these common assumptions. Although Watt’s
review occasioned the following comments, they have
broader public health implications.
The investigators of the Veterans Affairs — HDL-Choles-
terol Intervention Trial (VA-HIT) [2] were interested in
knowing how much of the 22% relative reduction in the
risk of the combined incidence of nonfatal myocardial
infarction and coronary death could be explained by the
individual increases in the surrogate marker, HDL-choles-
terol. The investigators included, in a regression analysis,
the individual changes in HDL-cholesterol between the
baseline and the 1-year visits and the treatment category
(gemfibrozil or placebo), and assessed their associations
with new coronary events occurring after the 1-year visit.
The relative risk of a major coronary event beyond 1 year
was 0.78 (95% confidence interval, 0.66–0.94) before
and 0.83 (95% confidence interval, 0.68–1.02) after the
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Abstract
Treatment decisions related to disease prevention are often based on two conventional and related
assumptions. First, an intervention-induced change in a surrogate marker (such as high-density
lipoprotein [HDL]-cholesterol) in the desired direction translates into health benefits (such as reduction
in coronary events). Second, it is unimportant which interventions are used to alter surrogate markers,
since an intervention benefit is independent of the means by which it is achieved. The scientific
foundation for these assumptions has been questioned. In this commentary, the appropriateness of
relying on low levels of HDL-cholesterol for treatment decisions is reviewed. The Veterans Affairs —
HDL-Cholesterol Intervention Trial (VA-HIT) investigators recently reported that only 23% of the
gemfibrozil-induced relative reduction in risk of coronary events observed in the trial could be explained
by changes in HDL-cholesterol between baseline and the 1-year visit. Thus, 77% of the health benefit
to the participants was unexplained. Other possible explanations are that gemfibrozil has multiple
mechanisms of action, disease manifestations are multifactorial, and laboratory measurements of HDL-
cholesterol are imprecise. The wisdom of relying on levels and changes in surrogate markers such as
HDL-cholesterol to make decisions about treatment choices should questioned. It seems better to rely
on direct evidence of health benefits and to prescribe specific interventions that have been shown to
reduce mortality and morbidity. Since extrapolations based on surrogate markers may not be in
patients' best interest, the practice of medicine ought to be evidence-based.
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adjustment for individual HDL-cholesterol changes. This
means that only 23% of the relative reduction in risk of
coronary events (relative risk from 0.78 to 0.83) in VA-HIT
can be explained by the individual 1-year changes in
HDL-cholesterol. In other words, 77% of the benefit of
gemfibrozil was unexplained and may be attributable to
other mechanisms that are presumably unrelated to
HDL-cholesterol. This observation comes as no surprise
because drugs have multiple mechanisms of action and
disease manifestations are multifactorial.
Several factors could have contributed to the low predic-
tive value of HDL-cholesterol change between baseline
and 1 year. The first factor is the variability in the labora-
tory method for determining HDL-cholesterol. The biologic
variability that could have been reduced by averaging
measurement over multiple visits is a second factor and,
finally, the impact of VA-HIT participants on the gemfibrozil
group (who stopped taking the study medication after the
1-year visit) would most probably have lowered the predic-
tive value. If these factors had been adjusted, and the
adjustment improved the predictability by 50%, the predic-
tion of the benefit of gemfibrozil in VA-HIT would increase
from 23 to 35%. Approximately two-thirds of benefit
would, however, still be unexplained. This raises questions
about the role of modification of the surrogate marker
HDL-cholesterol in prevention of coronary events. In the
context of VA-HIT, it appears that information on the
change in HDL-cholesterol between baseline and 1 year is
only moderately useful as a predictor of coronary events.
Other studies also provide arguments against the
HDL-cholesterol hypothesis. Watts contrasts findings from
VA-HIT with the Bezafibrate Infarction Prevention (BIP) trial
(see Table 1 in [1]). It is puzzling that, despite a threefold
greater increase in mean HDL-cholesterol in BIP (+18% in
BIP versus +6% in VA-HIT), the reduction in risk of coro-
nary events was about 2.5 times smaller than VA-HIT (–9%
in BIP versus –22% in VA-HIT). This observation is not a
strong endorsement of the usefulness of HDL-cholesterol
in predicting health benefits. One possible explanation of
this observation is that gemfibrozil and bezafibrate differ
substantially in their non-HDL-cholesterol-mediated mecha-
nism(s) of action. Play of chance and differences in study
design and populations could obviously also have con-
tributed to the observed trial differences.
In the Heart and Estrogen/Progestin Replacement Study
(HERS), hormone treatment raised HDL-cholesterol by a
net 10% compared with placebo [3]. This presumably
favorable surrogate effect did not translate into a reduc-
tion in major coronary events. Focusing on one interven-
tion effect (the increase in HDL-cholesterol levels) ignores
the many other known and unknown actions of hormones,
which in HERS appeared to offset any expected benefit
attributed to the increase in HDL-cholesterol.
The HERS experience is one more reminder of the limita-
tion of assuming that change in a surrogate marker
directly translates into health benefits. The Antihyperten-
sive and Lipid-Lowering Treatment to Prevent Heart
Attack Trial (ALLHAT) provided a similar reminder [4]. In
spite of a similar drug effect on the surrogate marker
blood pressure in the chlorthalidone and doxazosin
groups, the risk of cardiovascular events was 25% higher
in the latter group. Moreover, the presumed favorable
effects of doxazosin on lipids (including a small increase
in mean HDL-cholesterol) conveyed no observed benefit
on risk of coronary events. The effect of doxazosin on
HDL-cholesterol (and low-density lipoprotein-cholesterol)
levels, which is very small, seems to be unimportant from
a point of view of patient health.
These setbacks to the HDL-cholesterol hypothesis have
several potential implications. Clinically, we should recog-
nize that the predictive value of increases in HDL-choles-
terol may exist but that the predictability of an agent may
depend on the type of treatment and its effects on HDL
metabolism, rather than the magnitude of its effect on
plasma concentrations of HDL-cholesterol [5,6]. The
overall value of clinical monitoring of HDL-cholesterol
needs to be considered in the proper perspective. The
favorable health effect of gemfibrozil that is attributed pri-
marily to its non-HDL-cholesterol-mediated mechanisms
may not be a class effect of fibrates. Treatment guidelines
that promote any intervention that raises HDL-cholesterol
appear to rest on a soft foundation and would benefit from
better scientific evidence. Sound lifestyle modifications
are always advisable. A new major scientific challenge is
to identify the non-HDL-cholesterol mechanisms of action
that contribute to the significant clinical benefits of gemfi-
brozil. From a regulatory viewpoint, approving drugs based
on their actions on surrogate markers (such as HDL-
cholesterol) ought to be curtailed [7].
Assessing scientific evidence involves a major component
of judgment. It is, in my view, better to rely on scientific evi-
dence and avoid basing decisions on surrogate markers.
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